XVIVO — Xvivo Perfusion AB Balance Sheet
0.000.00%
- SEK16.98bn
- SEK16.52bn
- SEK597.54m
- 77
- 3
- 100
- 65
Annual balance sheet for Xvivo Perfusion AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | Interim Report |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 160 | 354 | 399 | 246 | 546 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 49.1 | 43.7 | 63.9 | 104 | 139 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 260 | 463 | 548 | 468 | 826 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 23.6 | 21.3 | 26.3 | 47.6 | 97.6 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 634 | 1,150 | 1,543 | 1,733 | 2,181 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 52.6 | 72.2 | 105 | 135 | 134 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 57 | 142 | 257 | 303 | 236 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 578 | 1,008 | 1,285 | 1,430 | 1,945 |
Total Liabilities & Shareholders' Equity | 634 | 1,150 | 1,543 | 1,733 | 2,181 |
Total Common Shares Outstanding |